California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• California State Teachers Retirement System increased its Dianthus Therapeutics stake by 155.5% in the first quarter, reaching 40,584 shares valued at about $3.4 million. Institutional investors collectively own 47.53% of DNTH.
• Analyst sentiment remains broadly positive, with HC Wainwright raising its price target to $158 and Truist lifting its target to $128; the stock has a “Moderate Buy” consensus and an average target of $124.27.
• Risks include ongoing losses and substantial insider selling: Dianthus reported a quarterly loss of $0.90 per share versus expectations of $0.85, while insiders sold 253,779 shares worth approximately $25.9 million over the past 90 days.

California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 155.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,584 shares of the company's stock after buying an additional 24,697 shares during the quarter. California State Teachers Retirement System owned 0.07% of Dianthus Therapeutics worth $3,406,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of DNTH. Wellington Management Group LLP increased its position in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. State Street Corp boosted its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company's stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Polar Capital Holdings Plc acquired a new stake in Dianthus Therapeutics in the 3rd quarter valued at approximately $29,434,000. Finally, Marshall Wace LLP acquired a new stake in Dianthus Therapeutics in the 3rd quarter valued at approximately $22,545,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target to $158. The firm improved several near-term EPS estimates, including Q3 2026, Q4 2026 and Q1 2027, while forecasting a potential shift to profitability by 2030. HC Wainwright Dianthus Therapeutics analyst estimates
• Positive Sentiment: Recent analyst actions remain supportive overall. Truist raised its target to $128, while coverage data shows a “Moderate Buy” consensus and an average target of approximately $124.27. New institutional positions, including a roughly $402 million stake disclosed by BlackRock, also provide a positive ownership signal. Truist raises Dianthus Therapeutics price target
• Neutral Sentiment: Analyst opinion is not unanimous. While most analysts rate DNTH Buy or Strong Buy, at least one analyst maintains a Sell rating, contributing to uncertainty around the stock’s elevated valuation and clinical-stage risk. Analysts conflicted on Dianthus Therapeutics
• Negative Sentiment: CEO Marino Garcia sold 166,000 shares for approximately $17.95 million, reducing his direct ownership by 71.77%. The transaction may pressure sentiment because it represents a substantial insider position reduction. Dianthus also recently missed quarterly EPS expectations, reporting a loss of $0.90 per share versus an expected loss of $0.85, and analysts still project a full-year loss of $3.94 per share. Dianthus Therapeutics CEO stock sale

Dianthus Therapeutics Stock Down 0.9%

Dianthus Therapeutics stock opened at $108.92 on Friday. The firm has a market cap of $5.95 billion, a PE ratio of -26.25 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $18.08 and a 52-week high of $114.55. The company's 50 day moving average is $94.72 and its two-hundred day moving average is $80.65.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $0.30 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the company's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 253,779 shares of company stock valued at $25,931,495. 3.02% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a report on Thursday. Raymond James Financial reissued a "strong-buy" rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $124.27.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source